Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMPRIMA

Financiado

Cerrado

Implementing Primaquine Single Low Dose in Africa

The 2021 World Malaria Report estimates that the number of clinical cases in 2020 was 241 million and the number of deaths was 627,000, an increase of 69,000 compared to 2019, a timely reminder to maintain good malaria control and... ver más

31/03/2027

UNISTRA

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITE DE STRASBOURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-01

HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04: Creating a sustainable clinical tri... ExpectedOutcome:This topic aims at supporting activities that are contributing to one or several of...

Innovación

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UNISTRA

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ASAAP-plus Clinical evaluation of AntimalarialS tri-therapy with AtovAq... 1M€ Cerrado

SAFIRE SAFETY OF ANTIMALARIALS IN THE FIRST TRIMESTER: AN ADAPTIVE... 5M€ Cerrado

PDC2022-133085-I00 DESARROLLO DE UNA NUEVA GENERACION DE FARMACOS ANTIMALARICOS... 138K€ Cerrado

GLOBALMED Artemisinin based combination therapy an illustration of th... 927K€ Cerrado

MALACTRES Multi drug resistance in malaria under combination therapy... 4M€ Cerrado

NotToKill-NotToDie Unrevealing dry season Plasmodium falciparum replication bio... 175K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2023-04-01
Fecha Fin: 2027-03-31

Líder del proyecto

UNIVERSITE DE STRASBOURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The 2021 World Malaria Report estimates that the number of clinical cases in 2020 was 241 million and the number of deaths was 627,000, an increase of 69,000 compared to 2019, a timely reminder to maintain good malaria control and introduce novel elimination strategies. In 2012, to further reduce malaria transmission and possibly reach elimination, the WHO recommended adding single low dose primaquine (SLDPQ) to artemisinin based treatments (ACTs) in low transmission settings and more recently in areas where artemisinin resistance is emerging. SLDPQ kills mature gametocytes, blocking the transmission between humans and mosquitoes and should see a reduction in the malaria burden with widespread deployment. Compounding the poor uptake of SLDPQ is the lack of child-friendly formulations of primaquine and lingering anxieties regarding primaquine-related acute haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency. Building on the good progress of the ‘Developing Paediatric Primaquine’ EDCTP2-funded project, aiming at prequalifying paediatric formulations, we have conceived the IMPRIMA project to support the adoption of SLDPQ by conducting a real-life implementation study using our flavoured primaquine for children. Key to our success is the unique triangle of interconnecting activities - clinical, community/sociological, and policy - all within a matrix of capacity building and strong coordination by all seven partners. Our ambitious proposal aims to demonstrate the safety, acceptability, and community benefit of SLDPQ in 3 African countries with different malaria epidemiologies. Engagement with the communities and policy makers are fundamental to effect a positive change in drug policy and contribute to malaria elimination. In parallel, capacity will be enhanced for conducting clinical trials and monitoring the evolution of antimalarial drugs resistance. We believe the IMPRIMA project fits extremely well with the priorities of this call.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores